Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Eastern Time on November 6, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
Coherus Oncology to Participate in Upcoming Investor ConferencesREDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (
NASDAQ: CHRS) today announced that the company will be webcasting its presentations at the following upcoming conferences:
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC’s upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 –
Coherus Oncology to Participate in Upcoming Investor ConferencesREDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (
NASDAQ: CHRS) today announced that the company will be webcasting its participation in the following upcoming conferences:
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
